NCT/Study#

NCT03601078 /

BB2121-MM-002

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: